SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, taking place in New York, including a fireside chat on Tuesday, September 9, 2025, at 5:35 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event.
About Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 29 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.
The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.
Great Place to Work® is the registered trademark of the Great Place to Work Institute and is used under license.
Contacts
Allan Kells
This email address is being protected from spambots. You need JavaScript enabled to view it.
Rose Ramseth
This email address is being protected from spambots. You need JavaScript enabled to view it.

November 06, 2025 November 06, 2025 November 04, 2025 October 01, 2025 September 08, 2025 |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load